Global Drug Screening Market by Product & Services, by Sample Type, by End User - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • ID: 4403116
  • Report
  • Region: Global
  • 212 pages
  • Allied Analytics LLP
1 of 3

Global Drug Screening Market by Product & Services [Equipment, Consumables {Assay Kits, Calibrators & Controls, Sample Collection Cups} and Laboratory Services], by Sample Type [Oral Fluid/Saliva, Breath, Hair, Other Samples {Blood & Sweat}], by End User [Workplace & Schools, Criminal Justice Systems & Law Enforcement Agencies, Drug Testing Laboratories, Drug Treatment Centers, Hospitals, Personal Users, Pain Management Centers] - Global Opportunity Analysis and Industry Forecast, 2017-2023

Drug screening is a type of test carried out to determine an individual’s scope and degree of drug abuse. The global drug screening market is expected to reach $9,447 million in 2023 from $5,214 million in 2016 registering a CAGR of 8.7% from 2017 to 2023. Drug testing is mandated imperative by many organizations and institutes to maintain an addiction free and sober workforce. Healthy and sober workforce helps maintain high productivity and a proper work environment. Special rules are issued by government regarding use of drug abuse in public places such as railway stations, airports etc. to ensure safety of local population. Use of performance enhancement drugs often termed as ‘doping’ is increasing problem in professional sports which is regulated by international sports organizations by establishing rules and prohibiting drugs.

Technological advancements in drug screening devices and upsurge in applications of these devices in market drives the drugs screening market. Moreover, increase in alcohol consumption and illicit use of prescribed drugs by ageing population, increase in government funding for drug testing programs augment market growth. However, the fact that drug testing is considered as a violation right in some countries, precision and accuracy issues regarding breath analyzers, ban on alcohol consumption in various countries restrain the market growth. The use of advanced technology in the drug testing devices and untapped emerging economies offer lucrative opportunities for the market players.

The global drug screening market is segmented based on equipment and services, sample type, end user, and geography. Based on equipment and services, the market is segmented into equipment, rapid testing devices, consumables and laboratory services. Equipment segment is further bifurcated by type into immunoassay analyzers, chromatography instruments and breath analyzers. Breath analyzer are further divided into fuel cell analyzers, semiconductor analyzers and other devices. Rapid testing devices are divided into oral fluid testing devices and urine testing devices. Consumables segment is further bifurcated into assay kits, calibrators and controls, samples collection cups and other materials such as gloves, cotton swabs, syringes and others.

Based on sample type, this market is bifurcated into urine, oral fluid/saliva, breath, hair and others (blood and sweat). Urine sample test is widely used as this sample can be collected without causing any pain to the patient and is one of the most convenient detection method. Thus, urine sample screening tests held a major share in this segment in the year 2015 and this trend is likely to continue over the forecast period. Hair sample is expected to grow at a remarkable CAGR and is the fastest growing segment in drug screening market.

Geographically, this market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the drug screening market in 2015, and is expected to retain its dominance throughout the forecast period. This is primarily attributed to the higher buying power, availability, and applications that favor the utilization of drug screening in this region. However, Asia-Pacific is expected to emerge as a lucrative area with significant growth potential, owing to the improvement in R&D facilities, available disposable income, and rapidly developing economic conditions.

KEY MARKET BENEFITS

The study provides an in-depth analysis of the global drug screening market, with current trends and future estimations to elucidate the imminent investment pockets.
A quantitative analysis from 2016 to 2023 to enable the stakeholders to capitalize on prevailing market opportunities is discussed.
Key market players are profiled and their strategies are analyzed thoroughly, which helps understand competitive outlook of the market.
Porters Five Forces model interprets the bargaining power of suppliers & buyers, threat of new entrants & substitutes, and competition among the key players.

KEY PLAYERS PROFILED

Alere, Inc.
Drägerwerk AG & Co. KGAA
Abbott Laboratories
Hoffmann-La Roche AG
Biorad Laboratories, Inc.
Siemens AG
Thermo Fisher Scientific, Inc.
Danaher Corporation
Quest Diagnostics Incorporated
Express Diagnostics International Inc.

KEY MARKET SEGMENTS:

By Product & Service

Equipment
Immunoassay Analyzers
Chromatography Instruments
Breath Analyzers
Fuel Cell Breathlyzers
Semiconductor Breathlyzers
Other Devices
Rapid Testing Devices
Urine Testing Devices
Urine Testing Cups
Dip Cards
Cassettes
Oral Fluid Testing Devices
Consumables
Assay Kits
Sample Collection Cups
Calibrators and Controls
Others
Laboratory Services

By Sample Type

Urine Sample
Breath Sample
Oral Fluid Sample
Hair Sample
Others (Blood and Sweat Samples)

By End User

Workplace and Schools
Drug Testing Laboratories
Criminal Justice System & Law Enforcement Agencies
Hospitals
Drug Treatment Centers
Pain Management Centers
Personal Users

By Geography

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Taiwan
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
South Africa
Rest of LAMEA

Other players in the value chain include (profiles not included in the report)

BioMerieux
Shimadzu
CannAmm Occupational Testing Services
Agilent Technologies
DiaSorin
Eiken
Merck
Fujirebio
Synergy Health PL.

READ MORE
Note: Product cover images may vary from those shown
2 of 3
CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS
3.4. PATENT ANALYSIS.

3.4.1. Patent analysis, by year (2010-2016)
3.4.2. Patent analysis, by region

3.5. REGULATIONS
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Stringent government regulations regarding drug abuse
3.6.1.2. Rise in awareness against drug abuse
3.6.1.3. Surge in funding for drug screening

3.6.2. Restraints

3.6.2.1. Consideration of drug screening as a violation of rights
3.6.2.2. Possible manipulation of drug screening tests

3.6.3. Opportunities

3.6.3.1. Development of novel drug screening tests
3.6.3.2. Tapping the emerging markets

CHAPTER 4 DRUG SCREENING MARKET, BY PRODUCT & SERVICE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. EQUIPMENT

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Immunoassay analyzers

4.2.4.1. Market size & forecast

4.2.5. Chromatography instruments

4.2.5.1. Market size and forecast

4.2.6. Breath analyzers

4.2.6.1. Semiconductor breath analyzers
4.2.6.2. Fuel cell analyzers
4.2.6.3. Market size and forecast

4.3. RAPID TESTING DEVICES

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.3.3.1. Urine testing devices

4.3.3.1.1. Market size and forecast
4.3.3.1.2. Urine testing cups (value and volume estimation)
4.3.3.1.3. U.S.

4.3.3.1.3.1.1. Market size and forecast
4.3.3.1.3.1.2. Market share analysis by competitors (2012-2016)

4.3.3.1.4. Canada

4.3.3.1.4.1.1. Market size and forecast
4.3.3.1.4.1.2. Market share analysis by competitors (2012-2016)

4.3.3.1.5. UK

4.3.3.1.5.1.1. Market size and forecast
4.3.3.1.5.1.2. Market share analysis by competitors (2012-2016)

4.3.3.1.6. Taiwan

4.3.3.1.6.1.1. Market size and forecast
4.3.3.1.6.1.2. Market share analysis by competitors (2012-2016)

4.3.3.1.7. Dip cards
4.3.3.1.8. Cassettes

4.3.3.2. Oral fluid testing devices

4.3.3.2.1. Market size and forecast

4.4. CONSUMABLES

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Assay kits

4.4.4.1. Market size and forecast

4.4.5. Sample collection cups

4.4.5.1. Market size and forecast

4.4.6. Calibrators and controls

4.4.6.1. Market size and forecast

4.4.7. Others

4.4.7.1. Market size and forecast

4.5. LABORATORY SERVICES

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

CHAPTER 5 DRUG SCREENING MARKET, BY SAMPLE TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. URINE

5.2.1. Market size and forecast

5.3. ORAL FLUID

5.3.1. Market size and forecast

5.4. BREATH

5.4.1. Market size and forecast

5.5. HAIR

5.5.1. Market size and forecast

5.6. OTHER SAMPLES (BLOOD AND SWEAT)

5.6.1. Market size and forecast

CHAPTER 6 DRUG SCREENING MARKET, BY END USER

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. WORKPLACES AND SCHOOLS

6.2.1. Market size and forecast

6.3. CRIMINAL JUSTICE SYSTEMS AND LAW ENFORCEMENT AGENCIES

6.3.1. Market size and forecast

6.4. DRUG TESTING LABORATORIES

6.4.1. Market size and forecast

6.5. DRUG TREATMENT CENTERS

6.5.1. Market size and forecast

6.6. HOSPITALS

6.6.1. Market size and forecast

6.7. PERSONAL USERS

6.7.1. Market size and forecast

6.8. PAIN MANAGEMENT CENTERS

6.8.1. Market size and forecast

CHAPTER 7 DRUG SCREENING MARKET, BY GEOGRAPHY

7.1. OVERVIEW
7.2. NORTH AMERICA

7.2.1. Key Market Trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast

7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast

7.3.3.1. Germany market size and forecast
7.3.3.2. UK market size and forecast
7.3.3.3. France market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast

7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. India market size and forecast
7.4.3.4. Australia market size and forecast
7.4.3.5. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast

7.5.3.1. Brazil market size and forecast
7.5.3.2. Turkey market size and forecast
7.5.3.3. South Africa market size and forecast
7.5.3.4. Rest of LAMEA market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. ALERE INC.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments

8.2. DRAGERWERK AG & CO. KGAA

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance

8.3. ABBOTT LABORATORIES

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments

8.4. BIO-RAD LABORATORIES, INC.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance

8.5. DANAHER CORPORATION

8.5.1. Company overview
8.5.2. Company Snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. EXPRESS DIAGNOSTICS INTERNATIONAL INC.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Key strategic moves and developments

8.7. F. HOFFMANN-LA ROCHE AG (ROCHE DIAGNOSTICS)

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. QUEST DIAGNOSTICS INCORPORATED

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance

8.9. SIEMENS AKTIENGESELLSCHAFT

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments

8.10. THERMO FISHER SCIENTIFIC INC.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll